Xiaozhe Li

No. 58, Zhongshan 2Nd Road
Guangzhou, 510080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Clinical implications and predictors of MRD resurgence in ASCT-eligible patients with NDMM: a real-world study in China.

Clinical implications and predictors of MRD resurgence in ASCT-eligible patients with NDMM: a real-world study in China.

Journal: Future oncology (London, England)

Published: June 12, 2026

Sustained MRD Negative for 4 Years Is a Significant Marker of Prognosis in Patients with High-Risk Multiple Myeloma.

Sustained MRD Negative for 4 Years Is a Significant Marker of Prognosis in Patients with High-Risk Multiple Myeloma.

Journal: Cancers

Published: March 31, 2026

Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis.

Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis.

Journal: Annals of medicine

Published: November 03, 2025

Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation.

Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation.

Journal: Cancer medicine

Published: August 27, 2025

Early Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram.

Early Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram.

Journal: Biomedicines

Published: December 05, 2024

Clinical Feature and Predictive Model for Transplanted Patients with Functional High-Risk Multiple Myeloma.

Clinical Feature and Predictive Model for Transplanted Patients with Functional High-Risk Multiple Myeloma.

Journal: Archives of medical research

Published: November 14, 2024

The characteristics of patients with multiple myeloma surviving over 10 years.

The characteristics of patients with multiple myeloma surviving over 10 years.

Journal: Frontiers in oncology

Published: September 03, 2024

Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period.

Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: June 29, 2024

The identification and correction of pseudohypercalcemia.

The identification and correction of pseudohypercalcemia.

Journal: Frontiers in oncology

Published: May 31, 2024

Development and validation of a chemotherapy tolerance prediction model for Chinese multiple myeloma patients: The TM frailty score.

Development and validation of a chemotherapy tolerance prediction model for Chinese multiple myeloma patients: The TM frailty score.

Journal: Frontiers in oncology

Published: November 20, 2022

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells.

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells.

Journal: Medical oncology (Northwood, London, England)

Published: October 30, 2022

Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma.

Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma.

Journal: Thrombosis journal

Published: October 15, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026